The Future of Biosimilars
Keywords:
Biosimilars, generic drugs, quality improvement, ecosystem, BPCI ActAbstract
Biosimilars are to Biologic products what generic drugs are to chemical products, a more affordable solution to the increasing drug pricing without sacrificing the quality of the treatment. There is much debate in the health care industry as to whether Biosimilars will deliver on the same success achieved by the generic products, which can amount to up to 80% in some cases. It is my view though that Biosimilars provide a viable path to cost reduction, quality improvement and affordable accessibility to medication. In fact, the introduction of lower costs Biologics as intended by the Biosimilar market will force competition within the therapeutics treatment market that will both exert pricing pressure as well as inspire innovation in the entire ecosystem.
References
. Chandra A, Vanderpuye-Orgle J.
Competition in the age of biosimilars.
Jama. 2015; 314(3):225-6.
. Chao J, Skup M, Alexander E, Tundia
N, Macaulay D, Wu E, Mulani P.
Nomenclature and traceability debate
for biosimilars: small-molecule
surrogates lend support for
distinguishable non proprietary names.
Advances in therapy. 2015;32(3):270-
. Epstein MS, Ehrenpreis ED, Kulkarni
PM. Biosimilars: the need, the
challenge, the future: the FDA
perspective. The American journal of
gastroenterology.2014; 109(12):1856.
. FDA, Implementation of the Biologics
Price Competition and Innovation Act
of 2009.
Retrieved:http://www.fda.gov/drugs/gui
dancecomplianceregulatoryinformation/
ucm215089.htm
. FDA, Information on Biosimilars.
Retrieved:http://www.fda.gov/Drugs/De
velopmentApprovalProcess/HowDrugs
areDevelopedandApproved/ApprovalA
pplications/TherapeuticBiologicApplicat
ions/Biosimilars/default.htm
. Goozner N. A cloudy dawn for
biosimilars. Modern Health Care. 2015;
(47): 24
. Mysler E, Pineda C, Horiuchi T, Singh
E, Mahgoub E, Coindreau J, Jacobs I.
Clinical and regulatory perspectives on
biosimilar therapies and intended
copies of biologics in rheumatology.
Rheumatology international. 2016;
(5):613-25.
. Mulcahy AW, Predmore Z, Mattke S.
The cost savings potential of biosimilar
drugs in the United States. Rand
Corporation. 2014. Retrieved:
https://www.rand.org/pubs/perspectives
/PE127.readonline.html
. Ramanan S, Grampp G. Drift,
evolution, and divergence in biologics
and biosimilars manufacturing. Bio
Drugs. 2014 ; 28(4):363-72.
. Sandoz Web: Biosimilars Can Help
Lower Costs and Increase Accesss.
Retrieved:http://www.sandozbiosimilars.com/en/biosimilars/whybiosimilars-matter-en/importanceen.shtml
